Baidu
map

J Arthroplasty:全关节置换手术切口关闭方法:双向倒钩缝合 vs 传统缝合

2012-12-27 J Arthroplasty 网络 zhanghaisen

研究设计流程 关节置换术中快速、有效的关闭手术切口是一项重要的操作步骤,其中双向倒钩缝合技术是近年来出现的一种较为新式的伤口关闭方法。近日,美国克利夫兰医疗基金会的Nicholas T. Ting, MD等实施了一项前瞻性随机对照研究,评估了双向倒钩缝合技术与传统打结缝合法关闭关节置换切开的临床效果。相关研究结果发表在最新一期的J Arthroplasty上。 在该研究中,共涉及全髋关节置


研究设计流程

关节置换术中快速、有效的关闭手术切口是一项重要的操作步骤,其中双向倒钩缝合技术是近年来出现的一种较为新式的伤口关闭方法。近日,美国克利夫兰医疗基金会的Nicholas T. Ting, MD等实施了一项前瞻性随机对照研究,评估了双向倒钩缝合技术与传统打结缝合法关闭关节置换切开的临床效果。相关研究结果发表在最新一期的J Arthroplasty上。
在该研究中,共涉及全髋关节置换病例25例,全膝关节置换病例35例,具体研究设计见图1。在手术相关并发症、缝合时间以及手术总体时间方面比较两种缝合技术的疗效差异。研究结果显示(表2-4),在切口关闭时间方面,双向倒钩缝合组显著快于普通缝合方法(9.3分钟vs 13.6分钟,P<0.005)。在术后3个月的临床随访中,两组的并发症发生率相当。作者认为,双向倒钩缝合技术可有效地关闭关节置换的手术切口,且节省手术操作时间和潜在的降低相应花费。



Abstract 
We performed a prospective, randomized clinical trial to evaluate the efficacy of using a bidirectional barbed suture compared with traditional sutures in the deep closure of primary total hip (25) and knee (35) arthroplasties. Complications, time to closure, and length of surgery were evaluated. Closure was noted to be significantly faster (9.3 vs 13.6 minutes, P < .005) in the barbed suture group. Wound-related complications were similar (3 cases) in both groups at 3-month follow-up. Although this study supports the use of barbed technology as a functionally comparable and more efficient modality of wound closure with the potential for costs savings based on reduced operative time, the cost-effectiveness of its adoption is institution dependent and will rely on the optimization of all other perioperative factors.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1742226, encodeId=340e1e4222671, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Fri May 17 04:39:00 CST 2013, time=2013-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710617, encodeId=a37a1e106176f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jul 03 04:39:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668561, encodeId=7f53166856170, content=<a href='/topic/show?id=29ec543e9b8' target=_blank style='color:#2F92EE;'>#手术切口#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54379, encryptionId=29ec543e9b8, topicName=手术切口)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fdc26348797, createdName=zhaohui6740, createdTime=Wed Apr 10 13:39:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355717, encodeId=ed8f1355e1740, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 29 04:39:00 CST 2012, time=2012-12-29, status=1, ipAttribution=)]
    2013-05-17 yxch48
  2. [GetPortalCommentsPageByObjectIdResponse(id=1742226, encodeId=340e1e4222671, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Fri May 17 04:39:00 CST 2013, time=2013-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710617, encodeId=a37a1e106176f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jul 03 04:39:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668561, encodeId=7f53166856170, content=<a href='/topic/show?id=29ec543e9b8' target=_blank style='color:#2F92EE;'>#手术切口#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54379, encryptionId=29ec543e9b8, topicName=手术切口)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fdc26348797, createdName=zhaohui6740, createdTime=Wed Apr 10 13:39:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355717, encodeId=ed8f1355e1740, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 29 04:39:00 CST 2012, time=2012-12-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1742226, encodeId=340e1e4222671, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Fri May 17 04:39:00 CST 2013, time=2013-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710617, encodeId=a37a1e106176f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jul 03 04:39:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668561, encodeId=7f53166856170, content=<a href='/topic/show?id=29ec543e9b8' target=_blank style='color:#2F92EE;'>#手术切口#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54379, encryptionId=29ec543e9b8, topicName=手术切口)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fdc26348797, createdName=zhaohui6740, createdTime=Wed Apr 10 13:39:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355717, encodeId=ed8f1355e1740, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 29 04:39:00 CST 2012, time=2012-12-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1742226, encodeId=340e1e4222671, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Fri May 17 04:39:00 CST 2013, time=2013-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710617, encodeId=a37a1e106176f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Jul 03 04:39:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668561, encodeId=7f53166856170, content=<a href='/topic/show?id=29ec543e9b8' target=_blank style='color:#2F92EE;'>#手术切口#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54379, encryptionId=29ec543e9b8, topicName=手术切口)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fdc26348797, createdName=zhaohui6740, createdTime=Wed Apr 10 13:39:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355717, encodeId=ed8f1355e1740, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 29 04:39:00 CST 2012, time=2012-12-29, status=1, ipAttribution=)]
    2012-12-29 zhaojie88

相关资讯

CA Cancer J Clin:Oncotype DX HER2检查结果不能作为乳腺癌治疗方案的决策标准

美国匹兹堡大学的研究者日前评估了Oncotype DX检查中观察到的人类表皮生长因子受体2(HER2)状态与免疫组织化学(IHC)和荧光原位杂交(FISH) 确定的HER2状态之间的一致性(J Clin Oncol. 2011;29:4279-4285)。他们的数据显示指南指定的IHC 和FISH联合方案确定的相当数量的HER2阳性乳腺癌病例中,用Oncotype DX检查往往得出HER2假阴性的

Am Heart J:结构性心脏病患儿多旁道更常见

       美国学者的一项研究表明,在结构性心脏病(SHD)患儿中多旁道更为常见,并且二者均可对消融转归造成负面影响。论文于2012年11月21日在线发表于《美国心脏杂志》(Am Heart J)。   罹患Ebstein畸形和心肌病等SHD时可出现多旁道。结构性缺损可影响快速心律失常的耐受性,并可使用治疗和消融复杂化。此项研

J Orthop Trauma:经内侧开放伤口复位、经皮螺钉固定开放性跟骨骨折的临床效果

开放性跟骨骨折在临床上时有发生,但对于其治疗策略,临床上尚无统一标准。近日,美国圣安东尼奥医学中心矫形及康复外科的Michael J. Beltran, MD等在最新一期的J Orthop Trauma上,对他们采用经内侧开放伤口复位、经皮螺钉固定开放性跟骨骨折的疗效效果进行的报道。他们的研究对象为II或III性开放性跟骨骨折病例,手术均在作者所在的2级创伤中心进行。共有17例连续性患者纳入该研究

Eur Heart J:房颤者中断用华法林 血栓栓塞风险升高

12月23日,丹麦学者在Eur Heart J发表的一项研究"Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation"表明,在房颤患者中,中断华法林治疗与治疗中断后前90天内的死亡或血栓-栓

Eur J Pharmacol:补骨脂二氢黄酮甲醚Bavachinin可作为抑制肿瘤血管生成的治疗剂

缺氧诱导因子1(HIF-1)有两个亚基,在缺氧情况下,HIF-1α会过度表达,HIF-1α转录活性的增加与肿瘤进展、血管生成、转移和侵袭密切相关。 近日European Journal of Pharmacology杂志上的一则研究证实天然化合物补骨脂二氢黄酮甲醚 Bavachinin在体外和体内有较强的抗血管生成活性。Bavachinin浓度依赖性抑制人KB癌(HeLa细胞的衍生细胞株)HIF

CA Cancer J Clin:肝细胞癌诊疗的新近进展

肝细胞癌( HCC)是为数不多的几十年来发生率一直呈上升趋势的癌症之一。因此,考虑到这一患者人群治疗方式的独特的复杂性,研究往往着眼于诊断的精确性和安全性等方面。在过去的十年间,非手术治疗平台获得进展,诊断和肝移植技术也有提高。应对挑战的难度主要在下以下几点:1)患者相关的变异性,诸如多种并存疾病的存在可能会影响到治疗方案的适用性;2)肝脏相关的变异性,肝硬化患者评分诸如 Child-Pugh 评

Baidu
map
Baidu
map
Baidu
map